Carbapenems: Past, present, and future

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 11, 2011, Pages 4943-4960

  Papp Wallace, Krisztina M ^a,c   Endimiani, Andrea ^a,b,c   Taracila, Magdalena A ^c   Bonomo, Robert A ^a,c  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AZITHROMYCIN; BETA LACTAM; BIAPENEM; CARBAPENEM; CEPHALOSPORIN; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLAVULANIC ACID; COLISTIN; DORIPENEM; ERTAPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; PANIPENEM PLUS BETAMIPRON; PENICILLIN G; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULBACTAM; TACHYPLESIN; TEICOPLANIN; THIENAMYCIN; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; DRUG MECHANISM; DRUG STRUCTURE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HYDROLYSIS; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY;

ANTI-BACTERIAL AGENTS; BETA-ALANINE; BETA-LACTAMS; CARBAPENEMS; CILASTATIN; DRUG COMBINATIONS; HUMANS; IMIPENEM; THIENAMYCINS;

EID: 80054693925     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00296-11     Document Type: Short Survey

References (257)

1. Abbanat, D., B. Morrow, and K. Bush. 2008. New agents in development for the treatment of bacterial infections. Curr. Opin. Pharmacol. 8:582-592.
2. Akama, H., et al. 2004. Crystal structure of the membrane fusion protein, MexA, of the multidrug transporter in Pseudomonas aeruginosa. J. Biol. Chem. 279:25939-25942. (Pubitemid 38798733)
3. Albers-Schonberg, G., et al. 1976. Abstr. 16th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 229. American Society for Microbiology, Washington, DC.
4. Ambler, R. P., et al. 1991. A standard numbering scheme for the class A β-lactamases. Biochem. J. 276(Pt. 1):269-270.
5. Armand-Lefevre, L., et al. 2003. Imipenem resistance in Salmonella enterica serovar Wien related to porin loss and CMY-4 β-lactamase production. Antimicrob. Agents Chemother. 47:1165-1168. (Pubitemid 36258359)
6. Ayala, J., A. Quesada, S. Vadillo, J. Criado, and S. Piriz. 2005. Penicillin-binding proteins of Bacteroides fragilis and their role in the resistance to imipenem of clinical isolates. J. Med. Microbiol. 54:1055-1064. (Pubitemid 41566776)
7. Balke, B., et al. 2006. Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients. Eur. J. Clin. Microbiol. Infect. Dis. 25:25-30. (Pubitemid 43207325)
8. Basker, M. J. 1982. The carbapenem family. J. Antimicrob. Chemother. 10:4-7. (Pubitemid 12047920)
9. Basker, M. J., et al. 1981. Synthesis of 6-unsubstituted olivanic acid analogues and their antibacterial activities. J. Antibiot. (Tokyo) 34:1224-1226. (Pubitemid 12174625)
10. Basker, M. J., R. J. Boon, and P. A. Hunter. 1980. Comparative antibacterial properties in vitro of seven olivanic acid derivatives: MM 4550, MM 13902, MM 17880, MM 22380, MM 22381, MM 22382 and MM 22383. J. Antibiot. (Tokyo) 33:878-884. (Pubitemid 11231474)
11. Bassetti, M., L. Nicolini, S. Esposito, E. Righi, and C. Viscoli. 2009. Current status of newer carbapenems. Curr. Med. Chem. 16:564-575.
12. Bayes, M., X. Rabasseda, and J. R. Prous. 2007. Gateways to clinical trials. Methods Find. Exp. Clin. Pharmacol. 29:697-735. (Pubitemid 351255461)
13. Beadle, B. M., and B. K. Shoichet. 2002. Structural basis for imipenem inhibition of class C β-lactamases. Antimicrob. Agents Chemother. 46:3978-3980. (Pubitemid 35403277)
14. Bebrone, C. 2007. Metallo-β-lactamases (classification, activity, genetic organization, structure, zinc coordination) and their superfamily. Biochem. Pharmacol. 74:1686-1701.
15. Bebrone, C., et al. 2008. Mutational analysis of the zinc- and substrate-binding sites in the CphA metallo-β-lactamase from Aeromonas hydrophila. Biochem. J. 414:151-159.
16. Bebrone, C., et al. 2009. The structure of the dizinc subclass B2 metallo-β-lactamase CphA reveals that the second inhibitory zinc ion binds in the histidine site. Antimicrob. Agents Chemother. 53:4464-4471.
17. Bellido, F., C. Veuthey, J. Blaser, A. Bauernfeind, and J. C. Pechere. 1990. Novel resistance to imipenem associated with an altered PBP-4 in a Pseudomonas aeruginosa clinical isolate. J. Antimicrob. Chemother. 25:57-68. (Pubitemid 20042490)
18. Bethel, C. R., et al. 2011. Exploring the inhibition of CTX-M-9 by β-lactamase inhibitors and carbapenems. Antimicrob. Agents Chemother. 55:3465-3475.
19. Bonacorsi, S., F. Fitoussi, S. Lhopital, and E. Bingen. 1999. Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 43:213-217. (Pubitemid 29079148)
20. Bornet, C., et al. 2003. Imipenem and expression of multidrug efflux pump in Enterobacter aerogenes. Biochem. Biophys. Res. Commun. 301:985-990. (Pubitemid 36279211)
21. Bou, G., G. Cervero, M. A. Dominguez, C. Quereda, and J. Martinez-Beltran. 2000. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of β-lactamases. J. Clin. Microbiol. 38:3299-3305.
22. Bradford, P. A., et al. 1997. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC β-lactamase, and the loss of an outer membrane protein. Antimicrob. Agents Chemother. 41:563-569. (Pubitemid 27098404)
23. Bradley, J. S., et al. 1999. Carbapenems in clinical practice: a guide to their use in serious infection. Int. J. Antimicrob. Agents 11:93-100. (Pubitemid 29114967)
24. Branch, C. L., et al. 1998. Novel C-2 substituted carbapenem derivatives. Part IV. Synthesis and biological activity of five membered heteroaromatic derivatives. J. Antibiot. (Tokyo) 51:210-220. (Pubitemid 28118962)
25. Brown, A. G., et al. 1976. Naturally-occurring β-lactamase inhibitors with antibacterial activity. J. Antibiot. (Tokyo) 29:668-669.
26. Bush, K., and G. A. Jacoby. 2010. Updated functional classification of β-lactamases. Antimicrob. Agents Chemother. 54:969-976.
27. Butterworth, D., M. Cole, G. Hanscomb, and G. N. Rolinson. 1979. Olivanic acids, a family of β-lactam antibiotics with β-lactamase inhibitory properties produced by Streptomyces species. I. Detection, properties and fermentation studies. J. Antibiot. (Tokyo) 32:287-294. (Pubitemid 9189889)
28. Cama, L. D., and B. G. Christensen. 1978. Total synthesis of thienamycin analogs. 1. Synthesis of the thienamycin nucleus and dl- decysteaminylthienamycin. J. Am. Chem. Soc. 100:8006-8007. (Pubitemid 9115604)
29. Cartwright, S. J., and S. G. Waley. 1983. β-Lactamase inhibitors. Med. Res. Rev. 3:341-382.
30. Cassidy, P. J., et al. 1981. Epithienamycins. II. Isolation and structure assignment. J. Antibiot. (Tokyo) 34:637-648. (Pubitemid 11002531)
31. Cerquetti, M., M. Giufre, R. Cardines, and P. Mastrantonio. 2007. First characterization of heterogeneous resistance to imipenem in invasive non-typeable Haemophilus influenzae isolates. Antimicrob. Agents Chemother. 51:3155-3161. (Pubitemid 350067522)
32. Cha, R. 2008. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Pharmacotherapy 28:295-300. (Pubitemid 351328901)
33. Chambers, H. F., M. Sachdeva, and S. Kennedy. 1990. Binding affinity for penicillin-binding protein 2a correlates with in vivo activity of β-lactam antibiotics against methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 162:705-710. (Pubitemid 20266163)
34. Charnas, R. L., and J. R. Knowles. 1981. Inhibition of the RTEM β-lactamase from Escherichia coli. Interaction of enzyme with derivatives of olivanic acid. Biochemistry 20:2732-2737. (Pubitemid 11038334)
35. Chouchani, C., R. Marrakchi, and A. El Salabi. 2011. Evolution of β-lactams resistance in Gram-negative bacteria in Tunisia. Crit. Rev. Microbiol. 37:167-177.
36. Chow, J. W., and D. M. Shlaes. 1991. Imipenem resistance associated with the loss of a 40 kDa outer membrane protein in Enterobacter aerogenes. J. Antimicrob. Chemother. 28:499-504.
37. Cirioni, O., et al. 2007. Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain. Antimicrob. Agents Chemother. 51:2005-2010. (Pubitemid 46903087)
38. Cole, M. 1980. 'β-Lactams' as β-lactamase inhibitors. Philos. Trans. R. Soc. Lond. B Biol. Sci. 289:207-223.
39. Copar, A., et al. 2002. Design, synthesis and bioactivity evaluation of tribactam beta lactamase inhibitors. Bioorg. Med. Chem. Lett. 12:971-975. (Pubitemid 34214987)
40. Costello, A. L., N. P. Sharma, K. W. Yang, M. W. Crowder, and D. L. Tierney. 2006. X-ray absorption spectroscopy of the zinc-binding sites in the class B2 metallo-β-lactamase ImiS from Aeromonas veronii bv. sobria. Biochemistry 45:13650-13658. (Pubitemid 44748511)
41. Cottagnoud, P., et al. 2003. Meropenem prevents levofloxacin-induced resistance in penicillin-resistant pneumococci and acts synergistically with levofloxacin in experimental meningitis. Eur. J. Clin. Microbiol. Infect. Dis. 22:656-662. (Pubitemid 37491618)
42. Crawford, P. A., K. W. Yang, N. Sharma, B. Bennett, and M. W. Crowder. 2005. Spectroscopic studies on cobalt(II)-substituted metallo-β-lactamase ImiS from Aeromonas veronii bv. sobria. Biochemistry 44:5168-5176. (Pubitemid 40476141)
43. Cuffini, A. M., et al. 1998. Entry of sanfetrinem into human polymorphonuclear granulocytes and its cell-associated activity against intracellular, penicillin-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:1745-1750. (Pubitemid 28311573)
44. Cullmann, W., and W. Dick. 1983. Investigations on β-lactamase stability of recently developed β-lactam compounds: study of enzyme kinetics. Zentralbl. Bakteriol. Mikrobiol. Hyg. A 254:413-422. (Pubitemid 13025344)
45. Cunha, B. A., N. S. Hamid, V. Krol, and L. Eisenstein. 2008. Safety of meropenem in patients reporting penicillin allergy: lack of allergic cross reactions. J. Chemother. 20:233-237. (Pubitemid 351797065)
46. Di Modugno, E., et al. 1994. In vitro activity of the tribactam GV104326 against gram-positive, gram-negative, and anaerobic bacteria. Antimicrob. Agents Chemother. 38:2362-2368. (Pubitemid 24304231)
47. Docquier, J. D., et al. 2009. Crystal structure of the OXA-48 β-lactamase reveals mechanistic diversity among class D carbapenemases. Chem. Biol. 16:540-547.
48. Drawz, S. M., et al. 2010. Inhibition of the class C β-lactamase from Acinetobacter spp.: insights into effective inhibitor design. Biochemistry 49:329-340.
49. Drusano, G. L., W. Liu, C. Fregeau, R. Kulawy, and A. Louie. 2009. Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant. Antimicrob. Agents Chemother. 53:2266-2273.
50. Dundar, D., and M. Otkun. 2010. In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains. Yonsei Med. J. 51:111-116.
51. Easton, C. J., and J. R. Knowles. 1982. Inhibition of the RTEM β-lactamase from Escherichia coli. Interaction of the enzyme with derivatives of olivanic acid. Biochemistry 21:2857-2862. (Pubitemid 12067503)
52. Endimiani, A., et al. 2010. Enhancing resistance to cephalosporins in class C β-lactamases: impact of Gly214Glu in CMY-2. Biochemistry 49:1014-1023.
53. Endimiani, A., et al. 2006. Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum β-lactamase. BMC Infect. Dis. 6:52.
54. Ermertcan, S., M. Hosgor, O. Tunger, and G. Cosar. 2001. Investigation of synergism of meropenem and ciprofloxacin against Pseudomonas aeruginosa and Acinetobacter strains isolated from intensive care unit infections. Scand. J. Infect. Dis. 33:818-821. (Pubitemid 33069519)
55. Fainstein, V., B. LeBlanc, S. Weaver, and G. P. Bodey. 1982. A comparative in vitro study of thienamycin. Infection 10:50-52. (Pubitemid 12184124)
56. Farra, A., S. Islam, A. Stralfors, M. Sorberg, and B. Wretlind. 2008. Role of outer membrane protein OprD and penicillin-binding proteins in resistance of Pseudomonas aeruginosa to imipenem and meropenem. Int. J. Antimicrob. Agents 31:427-433.
57. Fernandez-Cuenca, F., et al. 2003. Relationship between β-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J. Antimicrob. Chemother. 51:565-574. (Pubitemid 36336148)
58. Fernandez-Cuenca, F., L. Martinez-Martinez, A. Pascual, and E. J. Perea. 2003. In vitro activity of azithromycin in combination with amikacin, ceftazidime, ciprofloxacin or imipenem against clinical isolates of Acinetobacter baumannii. Chemotherapy 49:24-26. (Pubitemid 36469791)
59. Fonseca, F., E. H. Bromley, M. J. Saavedra, A. Correia, and J. Spencer. 2011. Crystal structure of Serratia fonticola Sfh-I: activation of the nucleophile in mono-zinc metallo-β-lactamases. J. Mol. Biol. 411:951-959.
60. Force, E., et al. 2009. Evaluation of meropenem alone and combined with rifampin in the guinea pig model of pneumococcal meningitis. Eur. J. Clin. Microbiol. Infect. Dis. 28:807-811.
61. Frase, H., Q. Shi, S. A. Testero, S. Mobashery, and S. B. Vakulenko. 2009. Mechanistic basis for the emergence of catalytic competence against carbapenem antibiotics by the GES family of β-lactamases. J. Biol. Chem. 284:29509-29513.
62. Fukasawa, M., et al. 1992. Stability of meropenem and effect of 1 β-methyl substitution on its stability in the presence of renal dehydropeptidase I. Antimicrob. Agents Chemother. 36:1577-1579.
63. Fukuoka, T., et al. 1993. Activity of the carbapenem panipenem and role of the OprD (D2) protein in its diffusion through the Pseudomonas aeruginosa outer membrane. Antimicrob. Agents Chemother. 37:322-327. (Pubitemid 23046577)
64. Gaibani, P., et al. 2011. Rapid increase of carbapenemase-producing Klebsiella pneumoniae strains in a large Italian hospital: surveillance period 1 March-30 September 2010. Euro Surveill. 16:pii=19800.
65. Galleni, M., G. Amicosante, and J. M. Frere. 1988. A survey of the kinetic parameters of class C β-lactamases. Cephalosporins and other β-lactam compounds. Biochem. J. 255:123-129.
66. Ganta, S. R., et al. 2009. Approaches to the simultaneous inactivation of metallo- and serine-β-lactamases. Bioorg. Med. Chem. Lett. 19:1618-1622.
67. Garau, G., et al. 2005. A metallo-β-lactamase enzyme in action: crystal structures of the monozinc carbapenemase CphA and its complex with biapenem. J. Mol. Biol. 345:785-795. (Pubitemid 39600934)
68. Gehrlein, M., H. Leying, W. Cullmann, S. Wendt, and W. Opferkuch. 1991. Imipenem resistance in Acinetobacter baumannii is due to altered penicillin-binding proteins. Chemotherapy 37:405-412.
69. Ghosh, A. S., A. K. Kar, and M. Kundu. 1999. Impaired imipenem uptake associated with alterations in outer membrane proteins and lipopolysaccharides in imipenem-resistant Shigella dysenteriae. J. Antimicrob. Chemother. 43:195-201. (Pubitemid 29082443)
70. Giamarellou, H., A. Antoniadou, and K. Kanellakopoulou. 2008. Acinetobacter baumannii: a universal threat to public health? Int. J. Antimicrob. Agents 32:106-119.
71. Giske, C. G., L. Buaro, A. Sundsfjord, and B. Wretlind. 2008. Alterations of porin, pumps, and penicillin-binding proteins in carbapenem resistant clinical isolates of Pseudomonas aeruginosa. Microb. Drug Resist. 14:23-30. (Pubitemid 351441848)
72. Goa, K. L., and S. Noble. 2003. Panipenem/betamipron. Drugs 63:913-926.
73. Gopalakrishnan, R., and D. Sureshkumar. 2010. Changing trends in antimicrobial susceptibility and hospital acquired infections over an 8 year period in a tertiary care hospital in relation to introduction of an infection control programme. J. Assoc. Physicians India 58(Suppl.):25-31.
74. Graham, D. W., et al. 1987. Inhibition of the mammalian β-lactamase renal dipeptidase (dehydropeptidase-I) by (Z)-2-(acylamino)-3-substituted- propenoic acids. J. Med. Chem. 30:1074-1090. (Pubitemid 17120791)
75. Guelfi, K. C., et al. 2008. In vitro evaluation of the antimicrobial activity of meropenem in combination with polymyxin B and gatifloxacin against Pseudomonas aeruginosa and Acinetobacter baumannii. J. Chemother. 20:180-185. (Pubitemid 351797057)
76. Hanaki, H., and K. Hiramatsu. 1999. Combination effect of teicoplanin and various antibiotics against hetero-VRSA and VRSA. Kansenshogaku Zasshi 73:1048-1053. (In Japanese.)
77. Hancock, R. E., and F. S. Brinkman. 2002. Function of Pseudomonas porins in uptake and efflux. Annu. Rev. Microbiol. 56:17-38. (Pubitemid 35217446)
78. Hantson, P., F. Leonard, J. M. Maloteaux, and P. Mahieu. 1999. How epileptogenic are the recent antibiotics? Acta Clin. Belg. 54:80-87. (Pubitemid 29282239)
79. Hashihayata, T., et al. 2001. Diastereoselective synthesis of (2R,4R)-2-aryl-4-hydroxypyrrolidine: preparation of the side chain of novel carbapenem. Chem. Pharm. Bull. (Tokyo) 49:1500-1502. (Pubitemid 33043289)
80. Hashihayata, T., H. Sakoh, Y. Goto, K. Yamada, and H. Morishima. 2002. Synthesis of the side chain of a novel carbapenem via iodine-mediated oxidative cyclization of (1R)-N-(1-aryl-3-butenyl)acetamide. Chem. Pharm. Bull. (Tokyo) 50:423-425. (Pubitemid 41685651)
81. Hashizume, T., F. Ishino, J. Nakagawa, S. Tamaki, and M. Matsuhashi. 1984. Studies on the mechanism of action of imipenem (N-formimidoylthienamycin) in vitro: binding to the penicillin-binding proteins (PBPs) in Escherichia coli and Pseudomonas aeruginosa, and inhibition of enzyme activities due to the PBPs in E. coli. J. Antibiot. (Tokyo) 37:394-400. (Pubitemid 14129492)
82. Hikida, M., K. Itahashi, A. Igarashi, T. Shiba, and M. Kitamura. 1999. In vitro antibacterial activity of LJC 11,036, an active metabolite of L-084, a new oral carbapenem antibiotic with potent antipneumococcal activity. Antimicrob. Agents Chemother. 43:2010-2016. (Pubitemid 29395201)
83. Hikida, M., K. Kawashima, M. Yoshida, and S. Mitsuhashi. 1992. Inactivation of new carbapenem antibiotics by dehydropeptidase-I from porcine and human renal cortex. J. Antimicrob. Chemother. 30:129-134.
84. Hiraiwa, Y., A. Morinaka, T. Fukushima, and T. Kudo. 2009. Metallo-β-lactamase inhibitory activity of phthalic acid derivatives. Bioorg. Med. Chem. Lett. 19:5162-5165.
85. Hirakata, Y., et al. 2009. Efflux pump inhibitors reduce the invasiveness of Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 34:343-346.
86. Hodgson, S. T., D. M. Hollinshead, and S. V. Ley. 1984. π-Allyltricarbonyliron lactone complexes in synthesis: application to the synthesis of the β-lactam antibiotic (+)-thienamycin J. Chem. Soc. Chem. Commun. (Camb.) 1984:494-496. (Pubitemid 14103052)
87. Huang, H., and R. E. Hancock. 1996. The role of specific surface loop regions in determining the function of the imipenem-specific pore protein OprD of Pseudomonas aeruginosa. J. Bacteriol. 178:3085-3090. (Pubitemid 26169348)
88. Huang, H., D. Jeanteur, F. Pattus, and R. E. Hancock. 1995. Membrane topology and site-specific mutagenesis of Pseudomonas aeruginosa porin OprD. Mol. Microbiol. 16:931-941.
89. Huang, H., R. J. Siehnel, F. Bellido, E. Rawling, and R. E. Hancock. 1992. Analysis of two gene regions involved in the expression of the imipenem-specific, outer membrane porin protein OprD of Pseudomonas aeruginosa. FEMS Microbiol. Lett. 76:267-273.
90. Hugonnet, J. E., L. W. Tremblay, H. I. Boshoff, C. E. Barry, III, and J. S. Blanchard. 2009. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 323:1215-1218.
91. Iglicar, P., I. Legen, G. Vilfan, L. Selic, and A. Prezelj. 2009. Permeability of a novel β-lactamase inhibitor LK-157 and its ester prodrugs across rat jejunum in vitro. J. Pharm. Pharmacol. 61:1211-1218.
92. Imada, A., et al. 1980. C-19393 S2 and H2, new carbapenem antibiotics. I. Taxonomy of the producing strain, fermentation and antibacterial properties. J. Antibiot. (Tokyo) 33:1417-1424. (Pubitemid 11186857)
93. Isoda, T., et al. 2006. Syntheses and pharmacokinetic studies of prodrug esters for the development of oral carbapenem, L-084. J. Antibiot. (Tokyo). 59:241-247. (Pubitemid 43854736)
94. Jacqueline, C., et al. 2005. In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49:45-51. (Pubitemid 40065771)
95. Kahan, J. S., et al. 1979. Thienamycin, a new β-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties. J. Antibiot. (Tokyo) 32:1-12. (Pubitemid 9104065)
96. Kaloyanides, G. J. 1994. Antibiotic-related nephrotoxicity. Nephrol. Dial. Transplant. 9(Suppl. 4):130-134. (Pubitemid 24249487)
97. Kalp, M., and P. R. Carey. 2008. Carbapenems and SHV-1 β-lactamase form different acyl-enzyme populations in crystals and solution. Biochemistry 47:11830-11837.
98. Kang, Y. K., et al. 2003. Synthesis and biological evaluation of novel 1 β-methylcarbapenems with isothiazoloethenyl side chains. Bioorg. Med. Chem. Lett. 13:463-466. (Pubitemid 36259714)
99. Kang, Y. K., et al. 1999. Synthesis and biological evaluation of novel 1β-methylcarbapenems having a new moiety at C-2. Bioorg. Med. Chem. Lett. 9:2385-2390. (Pubitemid 29391527)
100. Katayama, Y., H. Z. Zhang, and H. F. Chambers. 2004. PBP 2a mutations producing very-high-level resistance to β-lactams. Antimicrob. Agents Chemother. 48:453-459. (Pubitemid 38141701)
101. Kattan, J. N., M. V. Villegas, and J. P. Quinn. 2008. New developments in carbapenems. Clin. Microbiol. Infect. 14:1102-1111.
102. Kawamoto, I., et al. 2001. Synthesis and antibacterial activity of novel 1β-methyl carbapenems with cycloalkylamine moiety at the C-2 position. J. Antibiot. (Tokyo) 54:1080-1092. (Pubitemid 34110878)
103. Ke, W., C. R. Bethel, J. M. Thomson, R. A. Bonomo, and F. van den Akker. 2007. Crystal structure of KPC-2: insights into carbapenemase activity in class A β-lactamases. Biochemistry 46:5732-5740. (Pubitemid 46764122)
104. Kiffer, C. R., et al. 2005. In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii. Diagn. Microbiol. Infect. Dis. 52:317-322. (Pubitemid 41297570)
105. Kijima, K., et al. 2009. Pharmacokinetics analysis of tebipenem pivoxil in a phase II clinical trial in otolaryngological infections. Jpn. J. Antibiot. 62:143-154. (In Japanese.)
106. Kim, J. Y., et al. 2006. Structural basis for the extended substrate spectrum of CMY-10, a plasmid-encoded class C β-lactamase. Mol. Microbiol. 60:907-916.
107. Kobayashi, F., et al. 1982. Antimicrobial and β-lactamase inhibitory activities of carpetimycins A and B, new carbapenem antibiotics. Antimicrob. Agents Chemother. 21:536-544. (Pubitemid 12070517)
108. Kobayashi, Y. 2005. Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan. J. Infect. Chemother. 11:259-261. (Pubitemid 41570025)
109. Koga, T., et al. 2009. Affinity of tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53:1238-1241.
110. Kohler, T., M. Michea-Hamzehpour, S. F. Epp, and J. C. Pechere. 1999. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob. Agents Chemother. 43:424-427. (Pubitemid 29079192)
111. Kotsakis, S. D., V. Miriagou, E. Tzelepi, and L. S. Tzouvelekis. 2010. Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. Antimicrob. Agents Chemother. 54:4864-4871.
112. Kropp, H., et al. 1976. Abstr. 16th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 228. American Society for Microbiology, Washington, DC.
113. Kropp, H., J. G. Sundelof, J. S. Kahan, F. M. Kahan, and J. Birnbaum. 1979. Abstr. 19th Intersci. Conf Antimicrob. Agents Chemother., abstr. 231. American Society for Microbiology, Washington, DC.
114. Kropp, H., J. G. Sundelof, R. Hajdu, and F. M. Kahan. 1982. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase. Antimicrob. Agents Chemother. 22:62-70. (Pubitemid 12029995)
115. Kuroki, H., N. Tateno, H. Ikeda, and N. Saito. 2010. Investigation of pneumonia-causing pathogenic organisms in children and the usefulness of tebipenem pivoxil for their treatment. J. Infect. Chemother. 16:280-287.
116. Lakaye, B., A. Dubus, S. Lepage, S. Groslambert, and J. M. Frere. 1999. When drug inactivation renders the target irrelevant to antibiotic resistance: a case story with β-lactams. Mol. Microbiol. 31:89-101. (Pubitemid 29012151)
117. Lee, J. H., et al. 2003. Synthesis and biological activity of novel 1β-methylcarbapenems with oxyiminopyrrolidinylamide moiety. Bioorg. Med. Chem. Lett. 13:4399-4403. (Pubitemid 37490826)
118. Lee, K. S., et al. 2005. Novel 1β-methylcarbapenems with isoxazoloethenyl moieties containing carboxylic acid sodium salt. Bioorg. Med. Chem. Lett. 15:231-234. (Pubitemid 39575816)
119. Lee, S. O., et al. 2004. Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study. Antimicrob. Agents Chemother. 48:224-228.
120. Lepelletier, D., et al. 2010. Imipenem-resistant Pseudomonas aeruginosa gastrointestinal carriage among hospitalized patients: risk factors and resistance mechanisms. Diagn. Microbiol. Infect. Dis. 66:1-6.
121. Limansky, A. S., M. A. Mussi, and A. M. Viale. 2002. Loss of a 29-kilodalton outer membrane protein in Acinetobacter baumannii is associated with imipenem resistance. J. Clin. Microbiol. 40:4776-4778. (Pubitemid 35434989)
122. Lisa, M. N., L. Hemmingsen, and A. J. Vila. 2010. Catalytic role of the metal ion in the metallo-β-lactamase GOB. J. Biol. Chem. 285:4570-4577.
123. Livermore, D. M., et al. 2011. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int. J. Antimicrob. Agents 37:415-419.
124. Louie, A., et al. 2010. The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression. Antimicrob. Agents Chemother. 54:2646-2654.
125. Mahamoud, A., J. Chevalier, M. Baitiche, E. Adam, and J. M. Pages. 2010. An alkylaminoquinazoline restores antibiotic activity in Gram-negative resistant isolates. Microbiology 157:566-571.
126. Mainardi, J. L., et al. 1997. Carbapenem resistance in a clinical isolate of Citrobacter freundii. Antimicrob. Agents Chemother. 41:2352-2354.
127. Majiduddin, F. K., and T. Palzkill. 2005. Amino acid residues that contribute to substrate specificity of class A β-lactamase SME-1. Antimicrob. Agents Chemother. 49:3421-3427. (Pubitemid 41060591)
128. Mammeri, H., H. Guillon, F. Eb, and P. Nordmann. 2010. Phenotypic and biochemical comparison of the carbapenem hydrolyzing activity of five plasmid-borne AmpC β-lactamases. Antimicrob. Agents Chemother. 54:4556-4560.
129. Mammeri, H., P. Nordmann, A. Berkani, and F. Eb. 2008. Contribution of extended-spectrum AmpC (ESAC) β-lactamases to carbapenem resistance in Escherichia coli. FEMS Microbiol. Lett. 282:238-240. (Pubitemid 351569457)
130. Mandell, L. 2009. Doripenem: a new carbapenem in the treatment of nosocomial infection. Clin. Infect. Dis. 49(Suppl. 1):S1-S3.
131. Martinez-Martinez, L. 2008. Extended-spectrum β-lactamases and the permeability barrier. Clin. Microbiol. Infect. 14(Suppl. 1):82-89.
132. Marumo, K., T. Nagaki, and Y. Nakamura. 1996. Evaluation of high-level carbapenem resistance in atypical Serratia marcescens by a comparison with its revertants. J. Antimicrob. Chemother. 38:47-58. (Pubitemid 126449208)
133. Mastalerz, H., M. Menard, E. Ruediger, and J. Fung-Tomc. 1992. Synthesis and antibacterial activity of some novel 6-methyl- and 6-propenyl-substituted carbapenems. J. Med. Chem. 35:953-958.
134. Matsumoto, A., et al. 2007. The emergence of drug-resistant Streptococcus pneumoniae and host risk factors for carriage of drug-resistant genes in northeastern Japan. Jpn. J. Infect. Dis. 60:10-13. (Pubitemid 46443709)
135. Maveyraud, L., et al. 1998. Structural basis for clinical longevity of carbapenem antibiotics in the face of challenge by the common class A β-lactamases from the antibiotic-resistant bacteria. J. Am. Chem. Soc. 120:9748-9752. (Pubitemid 28462478)
136. Mena, A., et al. 2006. Characterization of a large outbreak by CTX-M-1-producing Klebsiella pneumoniae and mechanisms leading to in vivo carbapenem resistance development. J. Clin. Microbiol. 44:2831-2837. (Pubitemid 44228577)
137. Meroueh, S. O., et al. 2006. Three-dimensional structure of the bacterial cell wall peptidoglycan. Proc. Natl. Acad. Sci. U. S. A. 103:4404-4409.
138. Minond, D., et al. 2009. Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries. Bioorg. Med. Chem. 17:5027-5037.
139. Miranda-Novales, G., B. E. Leanos-Miranda, M. Vilchis-Perez, and F. Solorzano-Santos. 2006. In vitro activity effects of combinations of cephalothin, dicloxacillin, imipenem, vancomycin and amikacin against methicillin-resistant Staphylococcus spp. strains. Ann. Clin. Microbiol. Antimicrob. 5:25.
140. Misra, R., and V. N. Bavro. 2009. Assembly and transport mechanism of tripartite drug efflux systems. Biochim. Biophys. Acta 1794:817-825.
141. Miyadera, T., et al. 1983. Synthesis and in vitro activity of a new carbapenem, RS-533. J. Antibiot. (Tokyo) 36:1034-1039. (Pubitemid 13046928)
142. Miyashita, M., M. N. Chida, and A. Yoshikoshi. 1982. Synthesis of the precursor of (+)-thienamycin utilizing D-glucosamine. J. Chem. Soc Chem. Commun. (Camb.) 1982:1354-1356. (Pubitemid 13140497)
143. Miyazaki, S., et al. 2001. In vitro and in vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections. Antimicrob. Agents Chemother. 45:203-207. (Pubitemid 32039115)
144. Moellering, R. C., Jr., G. M. Eliopoulos, and D. E. Sentochnik. 1989. The carbapenems: new broad spectrum β-lactam antibiotics. J. Antimicrob. Chemother. 24(Suppl. A):1-7.
145. Monks, J., and S. G. Waley. 1988. Imipenem as substrate and inhibitor of β-lactamases. Biochem. J. 253:323-328.
146. Montravers, P., A. Andremont, L. Massias, and C. Carbon. 1994. Investigation of the potential role of Enterococcus faecalis in the pathophysiology of experimental peritonitis. J. Infect. Dis. 169:821-830. (Pubitemid 24102116)
147. Murakami, K., M. Doi, and T. Yoshida. 1982. Asparenomycins A, B and C, new carbapenem antibiotics. V. Inhibition of β-lactamases. J. Antibiot. (Tokyo) 35:39-45. (Pubitemid 12069738)
148. Muratani, T., K. Doi, T. Kobayashi, T. Nakamura, and T. Matsumoto. 2009. Antimicrobial activity of tebipenem against various clinical isolates from various specimen, mainly urinary tract. Jpn. J. Antibiot. 62:116-126. (In Japanese.)
149. Nakayama, M., et al. 1980. Carpetimycins A and B, new β-lactam antibiotics. J. Antibiot. (Tokyo) 33:1388-1390.
150. Neuwirth, C., E. Siebor, J. M. Duez, A. Pechinot, and A. Kazmierczak. 1995. Imipenem resistance in clinical isolates of Proteus mirabilis associated with alterations in penicillin-binding proteins. J. Antimicrob. Chemother. 36:335-342.
151. Nicasio, A. M., J. L. Kuti, and D. P. Nicolau. 2008. The current state of multidrug-resistant gram-negative bacilli in North America. Pharmacotherapy 28:235-249.
152. Nikaido, H. 1996. Multidrug efflux pumps of gram-negative bacteria. J. Bacteriol. 178:5853-5859. (Pubitemid 26337766)
153. Nix, D. E., A. K. Majumdar, and M. J. DiNubile. 2004. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J. Antimicrob. Chemother. 53(Suppl. 2):ii23-ii28.
154. Nordmann, P., M. H. Nicolas, and L. Gutmann. 1993. Penicillin-binding proteins of Rhodococcus equi: potential role in resistance to imipenem. Antimicrob. Agents Chemother. 37:1406-1409. (Pubitemid 23202361)
155. Nordmann, P., et al. 2011. Comparative activity of carbapenem testing: the COMPACT study. J. Antimicrob. Chemother. 66:1070-1078.
156. Norrby, S. R. 1996. Neurotoxicity of carbapenem antibacterials. Drug Saf. 15:87-90. (Pubitemid 26288228)
157. Norrby, S. R., et al. 1983. Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors. Antimicrob. Agents Chemother. 23:300-307. (Pubitemid 13137542)
158. Nozaki, Y., S. Harada, K. Kitano, and A. Imada. 1984. Structure-activity relations of 5,6-cis carbapenem antibiotics and role of factors determining susceptibility of Escherichia coli to β-lactam antibiotics. J. Antibiot. (Tokyo) 37:218-226. (Pubitemid 14172309)
159. Nukaga, M., et al. 2008. Inhibition of class A β-lactamases by carbapenems: crystallographic observation of two conformations of meropenem in SHV-1. J. Am. Chem. Soc. 130:12656-12662.
160. Nunez, L. E., C. Mendez, A. F. Brana, G. Blanco, and J. A. Salas. 2003. The biosynthetic gene cluster for the β-lactam carbapenem thienamycin in Streptomyces cattleya. Chem. Biol. 10:301-311. (Pubitemid 36516648)
161. Ochs, M. M., M. P. McCusker, M. Bains, and R. E. Hancock. 1999. Negative regulation of the Pseudomonas aeruginosa outer membrane porin OprD selective for imipenem and basic amino acids. Antimicrob. Agents Chemother. 43:1085-1090. (Pubitemid 29214729)
162. Okabe, M., et al. 1982. Studies on the OA-6129 group of antibiotics, new carbapenem compounds. I. Taxonomy, isolation and physical properties. J. Antibiot. (Tokyo) 35:1255-1263. (Pubitemid 13212101)
163. Okamura, K., et al. 1978. PS-5, a new β-lactam antibiotic from Streptomyces. J. Antibiot. (Tokyo) 31:480-482. (Pubitemid 8359947)
164. Oliver, A., B. R. Levin, C. Juan, F. Baquero, and J. Blazquez. 2004. Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections. Antimicrob. Agents Chemother. 48:4226-4233. (Pubitemid 39434879)
165. Osaki, Y., et al. 2005. Genetic approach to study the relationship between penicillin-binding protein 3 mutations and Haemophilus influenzae β-lactam resistance by using site-directed mutagenesis and gene recombinants. Antimicrob. Agents Chemother. 49:2834-2839. (Pubitemid 40917599)
166. Oteo, J., et al. 2008. Emergence of imipenem resistance in clinical Escherichia coli during therapy. Int. J. Antimicrob. Agents 32:534-537.
167. Paetzel, M., et al. 2000. Crystal structure of the class D β-lactamase OXA-10. Nat. Struct. Biol. 7:918-925.
168. Pai, H., et al. 2001. Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 45:480-484. (Pubitemid 32105284)
169. Pankuch, G. A., G. Lin, H. Seifert, and P. C. Appelbaum. 2008. Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Antimicrob. Agents Chemother. 52:333-336.
170. Papp-Wallace, K. M., et al. 2010. Substrate selectivity and a novel role in inhibitor discrimination by position 237 in the KPC-2 β-lactamase. Antimicrob. Agents Chemother. 54:2867-2877.
171. Papp-Wallace, K. M., et al. 2010. Elucidating the role of Trp105 in the KPC-2 β-lactamase. Protein Sci. 19:1714-1727.
172. Parker, W. L., et al. 1982. SQ 27,860, a simple carbapenem produced by species of Serratia and Erwinia. J. Antibiot. (Tokyo) 35:653-660. (Pubitemid 13221967)
173. Patel, G., and R. A. Bonomo. 2011. Status report on carbapenemases: challenges and prospects. Expert Rev. Anti Infect. Ther. 9:555-570.
174. Paterson, D. L. 2000. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs). Clin. Microbiol. Infect. 6:460-463. (Pubitemid 34966064)
175. Paterson, D. L. 2002. Serious infections caused by enteric gram-negative bacilli - mechanisms of antibiotic resistance and implications for therapy of gram-negative sepsis in the transplanted patient. Semin. Respir. Infect. 17:260-264. (Pubitemid 35453642)
176. Paterson, D. L., and R. A. Bonomo. 2005. Extended-spectrum β-lactamases: a clinical update. Clin. Microbiol. Rev. 18:657-686.
177. Paukner, S., L. Hesse, A. Prezelj, T. Solmajer, and U. Urleb. 2009. In vitro activity of LK-157, a novel tricyclic carbapenem as broad-spectrum β-lactamase inhibitor. Antimicrob. Agents Chemother. 53:505-511.
178. Pearson, J. P., C. Van Delden, and B. H. Iglewski. 1999. Active efflux and diffusion are involved in transport of Pseudomonas aeruginosa cell-to-cell signals. J. Bacteriol. 181:1203-1210. (Pubitemid 29119559)
179. Pernot, L., et al. 2001. Crystal structures of the class D β-lactamase OXA-13 in the native form and in complex with meropenem. J. Mol. Biol. 310:859-874. (Pubitemid 32695700)
180. Perron, K., et al. 2004. CzcR-CzcS, a two-component system involved in heavy metal and carbapenem resistance in Pseudomonas aeruginosa. J. Biol. Chem. 279:8761-8768. (Pubitemid 38295933)
181. Perry, C. M., and T. Ibbotson. 2002. Biapenem. Drugs 62:2221-2235.
182. Petrella, S., et al. 2008. Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A β-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. Antimicrob. Agents Chemother. 52:3725-3736.
183. Pfaendler, H. R., J. R. Gostel, R. B. Woodward, and G. Rihs. 1981. Structure, reactivity, and biological activity of strained bicyclic β-lactams. J. Am. Chem. Soc. 103:4526-4531. (Pubitemid 11028843)
184. Piddock, L. J., and Y. F. Jin. 1995. Activity of biapenem (LJC 10627) against 51 imipenem-resistant bacteria and selection and characterisation of biapenem-resistant mutants. J. Antimicrob. Chemother. 36:845-850.
185. Pierre, J., A. Boisivon, and L. Gutmann. 1990. Alteration of PBP 3 entails resistance to imipenem in Listeria monocytogenes. Antimicrob. Agents Chemother. 34:1695-1698. (Pubitemid 20259495)
186. Plantan, I., et al. 2007. 4-Substituted trinems as broad spectrum β-lactamase inhibitors: structure-based design, synthesis, and biological activity. J. Med. Chem. 50:4113-4121. (Pubitemid 47301743)
187. Poirel, L., J. D. Pitout, and P. Nordmann. 2007. Carbapenemases: molecular diversity and clinical consequences. Future Microbiol. 2:501-512. (Pubitemid 47578214)
188. Pongpech, P., et al. 2010. Antibacterial activity of carbapenem-based combinations against multidrug-resistant Acinetobacter baumannii. J. Med. Assoc. Thai. 93:161-171.
189. Queenan, A. M., and K. Bush. 2007. Carbapenemases: the versatile β-lactamases. Clin. Microbiol. Rev. 20:440-458, table of contents.
190. Queenan, A. M., W. Shang, R. Flamm, and K. Bush. 2010. Hydrolysis and inhibition profiles of β-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. Antimicrob. Agents Chemother. 54:565-569.
191. Raimondi, A., A. Traverso, and H. Nikaido. 1991. Imipenem- and meropenem-resistant mutants of Enterobacter cloacae and Proteus rettgeri lack porins. Antimicrob. Agents Chemother. 35:1174-1180.
192. Reading, C., and T. Farmer. 1984. The inhibition of periplasmic β-lactamase in Escherichia coli by clavulanic acid and other β-lactamase inhibitors. McGraw-Hill, New York, NY.
193. Riera, E., et al. 8 June 2011. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. J. Antimicrob. Chemother. doi:10.1093/jac/dkr232.
194. Rodloff, A. C., E. J. Goldstein, and A. Torres. 2006. Two decades of imipenem therapy. J. Antimicrob. Chemother. 58:916-929.
195. Rodriguez-Hernandez, M. J., et al. 2000. Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. J. Antimicrob. Chemother. 45:493-501.
196. Rodriguez-Martinez, J. M., L. Poirel, and P. Nordmann. 2009. Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53:1766-1771.
197. Rodriguez-Martinez, J. M., L. Poirel, and P. Nordmann. 2009. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53:4783-4788.
198. Rodriguez, C. H., et al. 2010. In vitro antimicrobials activity against endemic Acinetobacter baumannii multiresistant clones. J. Infect. Dev. Ctries. 4:164-167.
199. Rolinson, G. N. 1991. Evolution of β-lactamase inhibitors. Rev. Infect. Dis. 13(Suppl. 9):S727-S732.
200. Rossi, F. 2011. The challenges of antimicrobial resistance in Brazil. Clin. Infect. Dis. 52:1138-1143.
201. Salzmann, T. N., R. W. Ratcliffe, B. G. Christensen, and F. A. Boufford. 1980. A stereocontrolled synthesis of (+)-thienamycin. J. Am. Chem. Soc. 102:6161-6163. (Pubitemid 11242160)
202. Sanchez, P. A., J. H. Toney, J. D. Thomas, and J. M. Berger. 2009. A sensitive coupled HPLC/electrospray mass spectrometry assay for SPM-1 metallo-β-lactamase inhibitors. Assay Drug Dev. Technol. 7:170-179.
203. Santillana, E., A. Beceiro, G. Bou, and A. Romero. 2007. Crystal structure of the carbapenemase OXA-24 reveals insights into the mechanism of carbapenem hydrolysis. Proc. Natl. Acad. Sci. U. S. A. 104:5354-5359. (Pubitemid 47175684)
204. Schneider, K. D., M. E. Karpen, R. A. Bonomo, D. A. Leonard, and R. A. Powers. 2009. The 1.4 A crystal structure of the class D β-lactamase OXA-1 complexed with doripenem. Biochemistry 48:11840-11847.
205. Schneider, K. D., et al. 2011. Structures of the class D carbapenemase OXA-24 from Acinetobacter baumannii in complex with doripenem. J. Mol. Biol. 406:583-594.
206. Shahid, M., et al. 2009. β-lactams and β-lactamase-inhibitors in current- or potential-clinical practice: a comprehensive update. Crit. Rev. Microbiol. 35:81-108.
207. Shin, K. J., et al. 1998. Synthesis and biological properties of new 1 β-methylcarbapenems. Bioorg. Med. Chem. Lett. 8:1607-1612. (Pubitemid 28341595)
208. Simona, F., et al. 2009. Common mechanistic features among metallo-β-lactamases: a computational study of Aeromonas hydrophila CphA enzyme. J. Biol. Chem. 284:28164-28171.
209. Simona, F., et al. 2007. Protonation state and substrate binding to B2 metallo-β-lactamase CphA from Aeromonas hydrofila. Proteins 69:595-605. (Pubitemid 47623874)
210. Siroy, A., et al. 2005. Channel formation by CarO, the carbapenem resistance-associated outer membrane protein of Acinetobacter baumannii. Antimicrob. Agents Chemother. 49:4876-4883. (Pubitemid 41778897)
211. Smith, C. A., M. Caccamo, K. A. Kantardjieff, and S. Vakulenko. 2007. Structure of GES-1 at atomic resolution: insights into the evolution of carbapenamase activity in the class A extended-spectrum β-lactamases. Acta Crystallogr. D Biol. Crystallogr. 63:982-992. (Pubitemid 47346824)
212. Sodhi, M., S. S. Axtell, J. Callahan, and R. Shekar. 2004. Is it safe to use carbapenems in patients with a history of allergy to penicillin? J. Antimicrob. Chemother. 54:1155-1157. (Pubitemid 40136760)
213. Song, J. Y., H. J. Cheong, J. Lee, A. K. Sung, and W. J. Kim. 2009. Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model. Int. J. Antimicrob. Agents 33:33-39.
214. Sougakoff, W., et al. 2002. Structure of the imipenem-hydrolyzing class A β-lactamase SME-1 from Serratia marcescens. Acta Crystallogr. D Biol. Crystallogr. 58:267-274. (Pubitemid 34179197)
215. Souli, M., et al. 2009. Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-β- lactamase-producing Klebsiella pneumoniae isolates? Antimicrob. Agents Chemother. 53:2133-2135.
216. Spratt, B. G., V. Jobanputra, and W. Zimmermann. 1977. Binding of thienamycin and clavulanic acid to the penicillin-binding proteins of Escherichia coli K-12. Antimicrob. Agents Chemother. 12:406-409. (Pubitemid 8170520)
217. Stapleton, P. D., K. P. Shannon, and G. L. French. 1999. Carbapenem resistance in Escherichia coli associated with plasmid-determined CMY-4 β-lactamase production and loss of an outer membrane protein. Antimicrob. Agents Chemother. 43:1206-1210. (Pubitemid 29214748)
218. Sumita, Y., and M. Fukasawa. 1995. Potent activity of meropenem against Escherichia coli arising from its simultaneous binding to penicillin-binding proteins 2 and 3. J. Antimicrob. Chemother. 36:53-64.
219. Sunagawa, M., H. Matsumura, T. Inoue, M. Fukasawa, and M. Kato. 1990. A novel carbapenem antibiotic, SM-7338 structure-activity relationships. J. Antibiot. (Tokyo) 43:519-532. (Pubitemid 20165229)
220. Sunagawa, M., H. Matsumura, Y. Sumita, and H. Nouda. 1995. Structural features resulting in convulsive activity of carbapenem compounds: effect of C-2 side chain. J. Antibiot. (Tokyo) 48:408-416.
221. Sunagawa, M., et al. 1994. Novel quaternary ammonium carbapenems: 1 β-methyl-2-(5′-substituted pyrrolidinylthio) carbapenems. J. Antibiot. (Tokyo) 47:1337-1340. (Pubitemid 24373413)
222. Swaren, P., et al. 1998. X-ray analysis of the NMC-A β-lactamase at 1.64-A resolution, a class A carbapenemase with broad substrate specificity. J. Biol. Chem. 273:26714-26721. (Pubitemid 28471687)
223. Symmons, M. F., E. Bokma, E. Koronakis, C. Hughes, and V. Koronakis. 2009. The assembled structure of a complete tripartite bacterial multidrug efflux pump. Proc. Natl. Acad. Sci. U. S. A. 106:7173-7178.
224. Taibi, P., and S. Mobashery. 1995. Mechanism of turnover of imipenem by the TEM β-lactamase revisited. J. Am. Chem. Soc. 117:7600-7605.
225. Tally, F. P., N. V. Jacobus, and S. L. Gorbach. 1978. In vitro activity of thienamycin. Antimicrob. Agents Chemother. 14:436-438. (Pubitemid 9027814)
226. Tam, V. H., A. N. Schilling, R. E. Lewis, D. A. Melnick, and A. N. Boucher. 2004. Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents. Antimicrob. Agents Chemother. 48:4315-4321. (Pubitemid 39434892)
227. Tamber, S., and R. E. Hancock. 2006. Involvement of two related porins, OprD and OpdP, in the uptake of arginine by Pseudomonas aeruginosa. FEMS Microbiol. Lett. 260:23-29. (Pubitemid 43879760)
228. Tipper, D. J., and J. L. Strominger. 1965. Mechanism of action of penicillins: a proposal based on their structural similarity to acyl-D-alanyl-D-alanine. Proc. Natl. Acad. Sci. U. S. A. 54:1133-1141.
229. Torres, J. A., M. V. Villegas, and J. P. Quinn. 2007. Current concepts in antibiotic-resistant gram-negative bacteria. Expert Rev. Anti Infect. Ther. 5:833-843. (Pubitemid 47610946)
230. Tremblay, L. W., F. Fan, and J. S. Blanchard. 2010. Biochemical and structural characterization of Mycobacterium tuberculosis β-lactamase with the carbapenems ertapenem and doripenem. Biochemistry 49:3766-3773.
231. Trias, J., and H. Nikaido. 1990. Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 34:52-57. (Pubitemid 20019963)
232. Tsai, H. T., J. T. Wang, C. J. Chen, and S. C. Chang. 2008. Association between antibiotic usage and subsequent colonization or infection of extensive drug-resistant Acinetobacter baumannii: a matched case-control study in intensive care units. Diagn. Microbiol. Infect. Dis. 62:298-305.
233. Tsuji, N., et al. 1982. The structures of pluracidomycins, new carbapenem antibiotics. J. Antibiot. (Tokyo) 35:536-540. (Pubitemid 12046414)
234. Tune, B. M. 1994. Renal tubular transport and nephrotoxicity of beta lactam antibiotics: structure-activity relationships. Miner Electrolyte Metab. 20:221-231. (Pubitemid 24320006)
235. Tune, B. M., D. Fravert, and C. Y. Hsu. 1989. Thienamycin nephrotoxicity. Mitochondrial injury and oxidative effects of imipenem in the rabbit kidney. Biochem. Pharmacol. 38:3779-3783. (Pubitemid 19284027)
236. Ueda, Y., and V. Vinet. 1992. Synthesis and in vitro activity of novel quaternary ammonium carbapenems: 2-pyridiniopropyl and 1-pyridinioethyl carbapenems. J. Antibiot. (Tokyo) 45:940-953.
237. van Dam, V., N. Olrichs, and E. Breukink. 2009. Specific labeling of peptidoglycan precursors as a tool for bacterial cell wall studies. Chembiochem 10:617-624.
238. Vera-Cabrera, L., et al. 2010. In vitro activity of ACH-702, a new isothiazoloquinolone, against Nocardia brasiliensis compared with econazole and the carbapenems imipenem and meropenem alone or in combination with clavulanic acid. Antimicrob. Agents Chemother. 54:2191-2193.
239. Vilar, M., et al. 2001. Kinetic study of two novel enantiomeric tricyclic β-lactams which efficiently inactivate class C β-lactamases. Antimicrob. Agents Chemother. 45:2215-2223. (Pubitemid 32664459)
240. Villar, H. E., F. Danel, and D. M. Livermore. 1997. Permeability to carbapenems of Proteus mirabilis mutants selected for resistance to imipenem or other β-lactams. J. Antimicrob. Chemother. 40:365-370. (Pubitemid 27437955)
241. Visalli, M. A., M. R. Jacobs, and P. C. Appelbaum. 1998. Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology. Antimicrob. Agents Chemother. 42:953-955. (Pubitemid 28216390)
242. Walsh, T. R. 2008. Clinically significant carbapenemases: an update. Curr. Opin. Infect. Dis. 21:367-371.
243. Walsh, T. R. 2010. Emerging carbapenemases: a global perspective. Int. J. Antimicrob. Agents 36(Suppl. 3):S8-S14.
244. Wang, X., G. Minasov, and B. K. Shoichet. 2002. Noncovalent interaction energies in covalent complexes: TEM-1 β-lactamase and β-lactams. Proteins 47:86-96. (Pubitemid 34195257)
245. Wareham, D. W., and D. C. Bean. 2006. In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Ann. Clin. Microbiol. Antimicrob. 5:10.
246. Weaver, S. S., G. P. Bodey, and B. M. LeBlanc. 1979. Thienamycin: new β-lactam antibiotic with potent broad-spectrum activity. Antimicrob. Agents Chemother. 15:518-521. (Pubitemid 9152428)
247. Webster, D. P., et al. 2010. Emergence of carbapenem resistance due to porin loss in an extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae strain during meropenem therapy. Int. J. Antimicrob. Agents 36:575-576.
248. Weide, T., et al. 2010. NH-1,2,3-triazole-based inhibitors of the VIM-2 metallo-β-lactamase: synthesis and structure-activity studies. ACS Med. Chem. Lett. 1:150-154.
249. Woodward, R. B. 1980. Penems and related substances. Philos. Trans. R. Soc. Lond. B Biol. Sci. 289:239-250.
250. Wu, S., D. Xu, and H. Guo. 2010. QM/MM studies of monozinc β-lactamase CphA suggest that the crystal structure of an enzyme-intermediate complex represents a minor pathway. J. Am. Chem. Soc. 132:17986-17988.
251. Xu, D., D. Xie, and H. Guo. 2006. Catalytic mechanism of class B2 metallo-β-lactamase. J. Biol. Chem. 281:8740-8747.
252. Xu, D., Y. Zhou, D. Xie, and H. Guo. 2005. Antibiotic binding to monozinc CphA β-lactamase from Aeromonas hydropila: quantum mechanical/molecular mechanical and density functional theory studies. J. Med. Chem. 48:6679-6689. (Pubitemid 41504724)
253. Yong, D., et al. 2009. Characterization of a new metallo-β-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob. Agents Chemother. 53:5046-5054.
254. Zafaralla, G., and S. Mobashery. 1992. Facilitation of the delta2 to delta1 pyrroline tautomerization of carbapenem antibiotics by the highly conserved arginine-244 of class A beta-lactamases during the course of turnover. J. Am. Chem. Soc. 114:1506-1507.
255. Zhanel, G. G., et al. 2007. Comparative review of the carbapenems. Drugs 67:1027-1052. (Pubitemid 46744477)
256. Zhang, L., and S. Ma. 2010. Efflux pump inhibitors: a strategy to combat P-glycoprotein and the NorA multidrug resistance pump. ChemMedChem 5:811-822.
257. Ziha-Zarifi, I., C. Llanes, T. Kohler, J. C. Pechere, and P. Plesiat. 1999. In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM. Antimicrob. Agents Chemother. 43:287-291. (Pubitemid 29079160)